全文获取类型
收费全文 | 32399篇 |
免费 | 1730篇 |
国内免费 | 141篇 |
专业分类
耳鼻咽喉 | 349篇 |
儿科学 | 723篇 |
妇产科学 | 564篇 |
基础医学 | 6070篇 |
口腔科学 | 732篇 |
临床医学 | 2577篇 |
内科学 | 6060篇 |
皮肤病学 | 852篇 |
神经病学 | 3343篇 |
特种医学 | 1422篇 |
外科学 | 4531篇 |
综合类 | 151篇 |
一般理论 | 14篇 |
预防医学 | 1617篇 |
眼科学 | 718篇 |
药学 | 2308篇 |
中国医学 | 21篇 |
肿瘤学 | 2218篇 |
出版年
2021年 | 256篇 |
2020年 | 292篇 |
2019年 | 481篇 |
2018年 | 567篇 |
2017年 | 437篇 |
2016年 | 557篇 |
2015年 | 645篇 |
2014年 | 773篇 |
2013年 | 1163篇 |
2012年 | 1619篇 |
2011年 | 1742篇 |
2010年 | 1166篇 |
2009年 | 1124篇 |
2008年 | 1877篇 |
2007年 | 1915篇 |
2006年 | 1787篇 |
2005年 | 1916篇 |
2004年 | 1789篇 |
2003年 | 1756篇 |
2002年 | 1830篇 |
2001年 | 325篇 |
2000年 | 237篇 |
1999年 | 351篇 |
1998年 | 408篇 |
1997年 | 344篇 |
1996年 | 300篇 |
1995年 | 333篇 |
1994年 | 284篇 |
1993年 | 256篇 |
1992年 | 203篇 |
1991年 | 203篇 |
1990年 | 168篇 |
1989年 | 160篇 |
1988年 | 167篇 |
1987年 | 132篇 |
1985年 | 155篇 |
1984年 | 179篇 |
1983年 | 161篇 |
1982年 | 197篇 |
1981年 | 168篇 |
1978年 | 134篇 |
1933年 | 170篇 |
1932年 | 180篇 |
1931年 | 167篇 |
1930年 | 169篇 |
1929年 | 147篇 |
1928年 | 163篇 |
1927年 | 144篇 |
1926年 | 158篇 |
1925年 | 139篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Thomas Behrens Calvin Ge Roel Vermeulen Benjamin Kendzia Ann Olsson Joachim Schüz Hans Kromhout Beate Pesch Susan Peters Lützen Portengen Per Gustavsson Dario Mirabelli Pascal Guénel Danièle Luce Dario Consonni Neil E. Caporaso Maria Teresa Landi John K. Field Stefan Karrasch Heinz-Erich Wichmann Jack Siemiatycki Marie-Elise Parent Lorenzo Richiardi Lorenzo Simonato Karl-Heinz Jöckel Wolfgang Ahrens Hermann Pohlabeln Guillermo Fernández-Tardón David Zaridze John R. McLaughlin Paul A. Demers Beata Świątkowska Jolanta Lissowska Tamás Pándics Eleonora Fabianova Dana Mates Vladimir Bencko Lenka Foretova Vladimír Janout Paolo Boffetta Bas Bueno-de-Mesquita Francesco Forastiere Kurt Straif Thomas Brüning 《International journal of cancer. Journal international du cancer》2023,152(4):645-660
There is limited evidence regarding the exposure-effect relationship between lung-cancer risk and hexavalent chromium (Cr(VI)) or nickel. We estimated lung-cancer risks in relation to quantitative indices of occupational exposure to Cr(VI) and nickel and their interaction with smoking habits. We pooled 14 case-control studies from Europe and Canada, including 16 901 lung-cancer cases and 20 965 control subjects. A measurement-based job-exposure-matrix estimated job-year-region specific exposure levels to Cr(VI) and nickel, which were linked to the subjects' occupational histories. Odds ratios (OR) and associated 95% confidence intervals (CI) were calculated by unconditional logistic regression, adjusting for study, age group, smoking habits and exposure to other occupational lung carcinogens. Due to their high correlation, we refrained from mutually adjusting for Cr(VI) and nickel independently. In men, ORs for the highest quartile of cumulative exposure to CR(VI) were 1.32 (95% CI 1.19-1.47) and 1.29 (95% CI 1.15-1.45) in relation to nickel. Analogous results among women were: 1.04 (95% CI 0.48-2.24) and 1.29 (95% CI 0.60-2.86), respectively. In men, excess lung-cancer risks due to occupational Cr(VI) and nickel exposure were also observed in each stratum of never, former and current smokers. Joint effects of Cr(VI) and nickel with smoking were in general greater than additive, but not different from multiplicative. In summary, relatively low cumulative levels of occupational exposure to Cr(VI) and nickel were associated with increased ORs for lung cancer, particularly in men. However, we cannot rule out a combined classical measurement and Berkson-type of error structure, which may cause differential bias of risk estimates. 相似文献
2.
Care improves self-reported daily functioning of adolescents with emotional and behavioural problems
Verhage Vera Reijneveld Sijmen. A. Wunderink Charlotte Grietens Hans Almansa Josue Jansen Danielle E. M. C. 《European child & adolescent psychiatry》2022,31(11):1685-1693
European Child & Adolescent Psychiatry - Emotional and behavioural problems (EBP) have a negative impact on various life domains of adolescents. Receiving care for EBP may improve the... 相似文献
3.
4.
Pavlova Penka van Zanten Martijn Snoek Basten L. de Jong Hans Fransz Paul 《Chromosome research》2022,30(1):5-24
Chromosome Research - Functional changes of cells upon developmental switches and in response to environmental cues are often reflected in nuclear phenotypes, showing distinctive chromatin states... 相似文献
5.
6.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
7.
European Journal of Epidemiology - Existing research has found adverse short-term effects of the COVID-19 pandemic on mental health, but longer-term effects have been less documented. Using newly... 相似文献
8.
9.
Oosterhoff Marije Bosma Hans van Schayck Onno C. P. Joore Manuela A. 《Prevention science》2019,20(6):970-974
Prevention Science - In the article, ‘A Cost Analysis of School-Based Lifestyle Interventions’, we calculated the societal costs of two school-based lifestyle interventions: ‘the... 相似文献